GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » Buyback Yield %

NextGen Biomed (XTAE:NXGN) Buyback Yield % : -1.16 (As of Jun. 07, 2024)


View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

NextGen Biomed's current buyback yield was -1.16%.


NextGen Biomed Buyback Yield % Historical Data

The historical data trend for NextGen Biomed's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed Buyback Yield % Chart

NextGen Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only - - -10.05 -20.68 -

NextGen Biomed Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.80 -20.63 0.59 -0.63 -

Competitive Comparison of NextGen Biomed's Buyback Yield %

For the Medical Instruments & Supplies subindustry, NextGen Biomed's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextGen Biomed's Buyback Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NextGen Biomed's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where NextGen Biomed's Buyback Yield % falls into.



NextGen Biomed Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

NextGen Biomed's Buyback Yield for the fiscal year that ended in Dec. 2022 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 27.17954712
=0.00%

NextGen Biomed's annualized Buyback Yield for the quarter that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 2 / 21.3543372
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Jun. 2023) data.


NextGen Biomed Buyback Yield % Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


NextGen Biomed (XTAE:NXGN) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101
NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.